2BJ4 image
Entry Detail
PDB ID:
2BJ4
Title:
ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
Biological Source:
PDB Version:
Deposition Date:
2005-01-28
Release Date:
2005-02-16
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.21
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:ESTROGEN RECEPTOR
Chain IDs:A
Chain Length:252
Number of Molecules:1
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Description:ESTROGEN RECEPTOR
Chain IDs:B
Chain Length:252
Number of Molecules:1
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Description:PEPTIDE ANTAGONIST
Chain IDs:C, D
Chain Length:11
Number of Molecules:2
Biological Source:SYNTHETIC CONSTRUCT
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CCS B CYS CARBOXYMETHYLATED CYSTEINE
Ligand Molecules
Primary Citation
Delineation of a Unique Protein-Protein Interaction Site on the Surface of the Estrogen Receptor
Proc.Natl.Acad.Sci.USA 102 3593 ? (2005)
PMID: 15728727 DOI: 10.1073/PNAS.0407189102

Abstact

Recent studies have identified a series of estrogen receptor (ER)-interacting peptides that recognize sites that are distinct from the classic coregulator recruitment (AF2) region. Here, we report the structural and functional characterization of an ERalpha-specific peptide that binds to the liganded receptor in an AF2-independent manner. The 2-A crystal structure of the ER/peptide complex reveals a binding site that is centered on a shallow depression on the beta-hairpin face of the ligand-binding domain. The peptide binds in an unusual extended conformation and makes multiple contacts with the ligand-binding domain. The location and architecture of the binding site provides an insight into the peptide's ER subtype specificity and ligand interaction preferences. In vivo, an engineered coactivator containing the peptide motif is able to strongly enhance the transcriptional activity of liganded ERalpha, particularly in the presence of 4-hydroxytamoxifen. Furthermore, disruption of this binding surface alters ER's response to the coregulator TIF2. Together, these results indicate that this previously unknown interaction site represents a bona fide control surface involved in regulating receptor activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures